Multiple randomized clinical trials have shown a decreased mortality associated with screening mammography.
Introduction
Multiple randomized clinical trials have shown a decreased mortality associated with screening mammography. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] The BCDDP and other nonrandomized studies of mammographic screening have demonstrated detection of decreased tumor size, as well as a decreased incidence of nodal metastasis in a well-screened study population. [16] [17] [18] [19] However, the applicability of these results to a general population has been questioned because volunteers for the BCDDP study may have been more motivated to receive appropriate tests and treatment. The long-term results of high mammography rates in a service population showing significant reductions in mortality have only recently become available.
Since 1986, breast cancer detection and treatment have been a public health priority in Rhode Island. As a result of an initiative led by the Department of Health and by physicians in this state, Rhode Island has a high mammography screening rate. Due to the cultural environment, there is little migration into and out of the state, making the residents a stable population for study. The objective of this study was to determine the impact of a high rate of mammographic screening on breast cancer presentation and treatment in a general population. It was hypothesized that the widespread use of mammography would result in decreased tumor size with downward stage migration, a decrease in cancer-related mortality, and an increase in the use of breast conservation.
Methods
In 1987 and 1989, the Rhode Island Department of Health conducted telephone surveys of a minimum of 850 women who were Rhode Island residents over 40 years of age. In these surveys, women were asked if they had received biannual mammography if they were 40-49 years of age, or annual mammography if they were 50 years and older. Since 1990, as part of the CDC BRFSS, 24 the Department of Health has conducted annual random digit dialing telephone surveys of 1,600 to 3,800 respondents. If the respondent was a female Rhode Island resident, age 40 years or older, she was asked if she had undergone mammography in the past 2 years. We report the proportion of women having mammography from 1990 to 2001 for three age groups: 40-49 years, 50-64 years, and 65 years and older. Because different questions and techniques were used for the surveys in 1987 and 1989, the results are given but are not included in the analysis of trends. The proportion of women reporting mammography in the prior 2 years was analyzed using a χ 2 test to compare data from 1990-1992 and 2000-2001. Stata software (Version 8, College Station,Tex) was used to analyze all data. A P value of less than .05 was considered statistically significant.
Since October 1, 1986 , all cancers detected or treated in Rhode Island have been reported to the RICR. This database (forms created by Rocky Mountain Cancer Data Systems, Salt Lake City, Utah) is maintained as a collaboration between the Department of Health and the Hospital Association of Rhode Island. Breast cancer data are collected at the time of diagnosis with semiannual follow-up reports from all hospitals, physician offices, and radiation treatment centers. The initial data collected include tumor size, histology, hormone receptor status, nodal involvement, and summary stage defining local, regional, or distant disease. The semiannual reports include the date of visit, disease status, and additional treatments. From 1987 to 1994, 7 of 13 hospitals in Rhode Island, representing approximately 75% of all breast cancer cases, also reported the AJCC stage. 25 Since 1995,all hospitals in Rhode Island have reported both summary and AJCC stage. The data were validated by 100% visual review of all case abstracts,computerized edit checks of all cases, and 10% reabstraction audits. At the time of analysis, the last year for complete data entry was 2001.
The incidence rates of DCIS and invasive breast carcinoma in women were calculated using the cases entered into the database from 1987 to 2001. Cases in which the woman was a resident of another state but treated at a Rhode Island facility for her cancer were excluded. Lobular carcinoma in situ cases were not included in incidence calculations. All cancers that were not staged or that were reported with an unknown AJCC or summary stage were included in the calculations for invasive breast cancer incidence. Using data from the 1990 and 2000 United States Censuses, linear population growth was assumed between these two data points to calculate the yearly population for each age group (40-49 years, 50-64 years, and 65 years and older). The overall incidence was age-adjusted using the 2000 US Standard Population. 26 To calculate the percentage increase in in situ and invasive breast cancer, 3-year averages of incident data were used. Rate ratios were used to compare the difference in incidence between 1987-1989 and 1999-2001 .
To determine if increased mammographic screening resulted in a decrease in tumor size, the mean and median tumor diameters were determined for in situ and invasive tumors for each year from 1987 to 2001. Cases with no tumor size recorded were excluded from the analysis. A Student's t test was used to determine if there was a significant decrease in the mean tumor diameter over the study period. A nonparametric K sample test was used to evaluate the equality of the medians.
To analyze the degree of disease at presentation, the percentage of cases in each stage was calculated for AJCC and summary stage. Cases with an unknown stage were excluded from the analysis. A χ 2 test was used to compare 1987-1989 percentages to 1999-2001 percentages.
The number of women presenting in each stage was analyzed similarly to the overall incidence. Using the population of Rhode Island women age 40 years and older as the population at risk and the cases that occurred in women 40 years of age and older, an incidence rate was calculated for each stage of invasive breast cancer. Since mandatory reporting of AJCC stage began in 1995, the trend could not be explored in the earlier data. From 1987 to 1993, there was significant variation in the number of cases that were classified as unknown; from 1994 onward, there was a low, stable number of cases reported with unknown stage. Therefore, the rate ratio was analyzed for 1995-1997 and 1999-2001 .
The proportion of patients with positive lymph nodes and the degree of lymph node involvement was analyzed to determine whether mammographic detection of smaller tumors had an impact on the extent of disease at presentation. Using pathology data, the number of positive lymph nodes in each case of invasive breast cancer was tabulated from 1995 to 2001. The proportion of cases with positive lymph nodes was compared between 1995-1997 and 1999-2001 . A separate analysis to determine the extent of lymph node involvement was then performed. The proportion of one, two or three, and four or greater positive lymph nodes was compared between 1995-1997 and 1999-2001 . Cases in which the nodal status was unknown were excluded from analysis. The data were compared using a χ 2 test. It is easier to perform BCS in patients with smaller primary cancers. To determine if mammographic screening had an impact on breast conservation utilization, the proportion of women treated with BCS (with or without radiotherapy) was determined from 1995 to 2001 for each age group. Comparison of the rate of BCS over time was made using data from 1995-1997 and 1999-2001 . When comparing the rate of BCS between age groups, data from 1999-2001 were used. Comparisons were analyzed using a χ 2 test. For the purposes of our study, only deaths due to breast cancer were used in calculating disease-specific mortality. Age-specific and overall mortality rates were determined from death certificate information obtained from the National Center for Health Statistics. The overall rate was age-adjusted using the 2000 US Standard Population. The change in mortality was analyzed by comparing the rate ratio of 1987-1989 to 1998-2000.
Results
The healthcare community in Rhode Island has aggressively promoted breast cancer screening since 1986. Overall, there has been an increase in mammographic screening for all age groups in Rhode Island (Fig 1) 
Ductal Carcinoma In Situ
Over the 15-year study period, the incidence of DCIS steadily increased 169%, from 12.5 to 33.5 per 100,000 (P<.01) (Fig 2) . For women 40-49 years of age, the incidence increased 263%, from 16.7 to 60.7 per 100,000 from 1987-1989 to 1999-2001 (P<.001). For the age group 50-64 years,the incidence of in situ breast cancer increased 126%, from 35.8 to 80.7 per 100,000 (P<.001). For women 65 years and older, the incidence increased 182%, from 30.7 to 86.6 per 100,000 (P<.001). Evaluation of data from the latter years of the study suggests that a plateau in the incidence of in situ breast cancer has not yet been reached.
Data on in situ tumor size were available for 23% of the reported cases in the tumor registry. For the available cases, the mean tumor size of DCIS decreased from 1.8 ± Data were available on tumor size for 79% of invasive breast cancers reported to the RICR. The mean tumor diameter decreased 23%, from 2.5 ± 1.9 cm to 2.0 ± 1. (Fig 4) .
To determine if there was stage migration over the study period, the percentage of cases in each AJCC or summary stage was calculated. The trends were similar for AJCC and summary stage, suggesting that there was no bias in the stage at presentation for the hospitals that did not initially report using AJCC stage. For all women, there was stage migration over the 15-year study period. 
Mean Tumor Size Median Tumor Size
Tumor size (cm) To ensure that the decrease in stage III and IV cancers was due to a decrease in absolute number of cases rather than a relative decrease in comparison to increased detection of stage I cancers, the incidence of stage I-IV cancers was calculated. Because all hospitals did not initially report AJCC stage, the comparison is made using 1995-1997 vs 1999-2001 (Table 2 ). There was no significant change in the incidence of stage I and II cancers from 1995-1997 compared with 1999-2001. There is a significant decrease in the incidence of stage III cancers from 21 to 16.4 per 100,000 (P=.0327). There is also a significant decrease in the incidence of stage IV cancers from 15.2 to 11.5 per 100,000 (P=.0497).
Beginning in 1995, the lymph node status and the number of lymph nodes involved with metastatic breast cancer were recorded in the RICR. (Table 1) Over the same time periods, there was a significant increase in the rate of BCS for women age 50-64 years and 65 years and older for stage I cancer. There was no significant difference in the rate of BCS among the age groups for stage I cancer.
For stage II disease treated in 1995 to 2001, the overall rate of BCS for all women was 51%. There was a significant increase in the rate of BCS in the group of women 50-64 years old for stage II cancer from 1995-1997 vs 1999-2001 (Table 1) . For the age groups 40-49 years and 65 years and older, there was no significant change in the rate of BCS. Women 65 years and older were significantly less likely than younger women to receive BCS for stage II disease for the period 1999-2001: 47% for those 65 years and older compared with 57% for women 40-49 years (P=.02) and 61% for women 50-64 years (P=.001).
The overall age-adjusted mortality attributable to breast cancer decreased 25% over the study period (Fig 6) . For all women diagnosed with breast cancer in Rhode Island, mortality decreased from 38.0 per 100,000 in 1987-1989 to 28.4 per 100,000 in 1998-2000 (P<.001). For women 40-49 years, the mortality rate decreased 28%, from 32.2 to 23.2 deaths per 100,000 (P=.099). For women 50-64 years, the mortality rate decreased 39%, from 82.9 to 50.4 per 100,000 (P<.001). For women 65 
Discussion
Since 1963,eight major randomized clinical trials have been conducted to determine the effect of screening mammography on mortality from breast cancer. The relative risk of dying from breast cancer in the group invited to screening varies from 0.60 to 1.29, with most trials showing a significant decrease in mortality from breast cancer. [1] [2] [3] [4] [5] [6] [7] [8] Given the reduction in mortality that was found by most of the trials, most advisory panels recommend annual screening for women over the age of 50 years and either annual or biannual screening for women 40-49 years. 15 However,in 1987, according to the National Health Interview Survey, only 29.1% of women age 50 years and older reported having a mammogram in the past 2 years,nationwide. 27 By 1998,the percentage had increased to 68.9%. 28 However, the BRFSS survey undertaken in 2002 by the CDC reported that of women age 40 years and above, 75.9% had received a mammogram in the prior 2 years. 24 Since the 1980s, the Rhode Island medical community has been committed to increasing the rate of screening mammography. By 2000, the Healthy People 2010 goal of a 70% screening mammography rate had been exceeded by 20%. 29 For women over the age of 40, Rhode Island has had greater than 80% biannual mammographic screening since 1997. Of the three age groups, mammographic screening rates were highest for women 50-64 years old, with an average rate of 88% in 1999-2001. Over the study period, women age 40-49 years showed the smallest absolute gain in screening, likely due to the conflicting messages regarding the benefit of screening mammography presented in the literature and the press in the 1990s. [30] [31] [32] Prior reports from Rhode Island and other states have suggested that women from lower socioeconomic groups and minorities are underscreened for breast cancer. [33] [34] [35] In 1996, only 37% of those women eligible for the Women's Cancer Screening Program, a CDC-sponsored program offering free mammography to women of low income, appear to have had screening mammography. Although based on a small sample size, data have shown a slight decline in the percentage of black Rhode Island women 40-49 years receiving mammography in the mid 1990s. Hispanic women in this same study showed a decrease in mammography across all age groups. 36 One of the limitations of our study is the method by which respondents are located in order to assess mammography rates. The populations likely to have the lowest rates of mammography screening are also the least likely to be included in the survey due to communication difficulties or lack of a telephone. In the continued effort to improve mammographic screening rates, these groups should be targeted. Another limitation of the assessment of mammography in this study is recall or reporting bias from the respondents.
Ductal Carcinoma In Situ
The high rate of mammographic screening in Rhode Island has had an impact on disease presentation. As with other studied populations, the incidence of DCIS has steadily increased. 37-39 From 1975 37-39 From -2000 , SEER data show an increase in DCIS from 5.8 to 32.7 per 100,000 in all women and an increase in women older than 50 years from 11.2 to 87.7 per 100,000, similar to observations in Rhode Island. 36 For women of all ages, we have experienced a 169% increase in the incidence of DCIS over 15 years. The greatest increase, 263%, was in women 40-49 years of age. Even with high screening rates in the 1980s and 1990s, we have not seen a plateau of rates of DCIS in any age group.
The continued increase in DCIS may signify improved mammographic techniques that detect more subtle abnormalities. It may also reflect that radiologists and pathologists now diagnose DCIS in lesions that would have previously been ignored radiographically or called atypia on histology. The increased detection and diagnosis of DCIS should be further explored because this rise could lead to a higher rate of treatment of lesions that are not biologically aggressive. On the other hand, the increase in DCIS, in conjunction with relatively stable invasive cancer rates, may indicate improved detection of tumors in a Year of diagnosis Deaths per 100,000 population preinvasive state. If this is true, further follow-up studies of well-screened populations should show a decrease in the incidence of invasive cancer. 40 To date, it is not possible to determine which cases of DCIS will progress to invasive cancer and which will remain as in situ disease. 41 Until prognostic factors are elucidated that will allow observation of the subset of DCIS that is unlikely to progress to invasive cancer, aggressive screening and excision of all cases of DCIS are warranted.
It is difficult to comment on any changes in the diagnosis and treatment of DCIS relative to diameter at presentation because tumor size was reported in only 23% of women with DCIS. This proportion has not varied significantly across the 15 years studied, with only 30% of DCIS in 2001 associated with a reported diameter. While the determination of an exact diameter of DCIS on pathology is difficult, information on the extent of DCIS will improve the care provided to women in Rhode Island. This issue needs to be addressed in education regarding the treatment of DCIS and the pathology reporting system for the state.
During the course of this study, the NSABP-B17, EORTC 10853, and other trials were published, showing that women treated with lumpectomy and radiation for DCIS had a significantly lower local recurrence rate than those treated with lumpectomy alone. Additionally, the trials also confirmed that DCIS could be treated by BCS with acceptable recurrence and mortality. [42] [43] [44] [45] These results may have had an impact on surgical treatment for DCIS. In Rhode Island, there was a significant increase in the overall rate of BCS for DCIS from 1995-1997 to 1999-2001. This was mainly influenced by the large increase in the proportion of women 50-64 years of age receiving BCS. For the subgroup of women age 40-49 years, there was a nonsignificant increase in the rate of BCS for DCIS. However, with an overall rate of 72%, the percentage of women receiving BCS in Rhode Island is significantly higher than results reported in other regions of the country. [46] [47] [48] Although they found rates of BCS for all groups to be close to 50%, a review of the National Cancer Data Base by Winchester et al 47 also reported the highest rates in the oldest age group. The significantly lower rate of BCS for women age 40-49 years may be appropriate, considering that DCIS may have a more aggressive nature in the younger population.
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Invasive Breast Cancer
Using data from the CDC's National Program of Cancer Registries and the SEER database, from 1996 to 2000 the national age-adjusted incidence of breast cancer was estimated to be 131.7 per 100,000. This incidence ranged from 104.5 per 100,000 in Mississippi to 145.2 per 100,000 in Massachusetts. 29 We found the age-adjusted incidence rate of invasive breast cancer in Rhode Island to be 133.5 per 100,000 from 1999 to 2001.
Our results show that a high rate of screening mammography does not result in a continued increase in the incidence of invasive breast cancer. There was no significant change in the overall incidence of invasive breast cancer during our study period. Given the high penetration of screening, these rates should reflect the true incidence of breast cancer in the state.
The BCDDP and other studies have shown a decrease in tumor size with increased mammographic screening. [16] [17] [18] [19] Our data also show that an increased rate of screening mammography has resulted in earlier detection of invasive breast cancer and smaller tumor size. Between 1987 and 2001 in Rhode Island, the mean tumor size decreased from 2.5 cm to 2.0 cm. The median tumor size, a more accurate indicator of the usual tumor size at presentation, decreased from 2.0 cm to 1.5 cm. From 1992-2001, the median tumor size has not decreased significantly. However, there has been a continued decrease in mean tumor size during the last 10 years of the study, illustrating the continued impact of screening mammography.
As would be expected with detection of smaller tumors, there was significant downward stage migration (Fig 5) . Both the relative number and absolute number of women presenting with stage III and IV breast cancer decreased during the study period (Table 2 ). Given the trend of an increase in stage II cancer incidence, most of the decrease in stage III and IV cancers may be explained by early detection when the cancers are graded as stage II.
Further illustrating the effects of high screening rates in the state, Rhode Island women presented with earlier breast cancer than ones monitored in the SEER database during the same years. The 1992-1998 SEER data showed 48.1% stage I, 49.8% stage II, 7.3% stage III, and 4.8% stage IV breast cancer at presentation. 51 In Rhode Island for the same time period, women presented with earlier AJCC stages: 53.5% stage I, 36.2% stage II, 6.2% stage III, and 3.9% stage IV. For patients who presented with N1 disease, the extent of nodal involvement decreased during our study period, with women presenting with fewer positive lymph nodes.
A decrease in size and stage should allow for an increase in breast conservation. Overall, 72% of stage I and 51% of stage II breast cancers were treated with BCS. From 1995-1997 to 1999-2001, there was a significant increase in the rate of BCS for women in age group 50-64 years with stage I and II disease and for women 65 years and older with stage I disease. While the major trials comparing breast conservation and mastectomy were completed by 1995, reports of sentinel node biopsy for breast cancer were first published during our study period, 1995-2001. [52] [53] [54] [55] [56] [57] The decreased morbidity associated with a sentinel node biopsy vs axillary dissection, along with increased physician and patient awareness of the benefits of BCS, may partially explain the increased use of BCS. However, BCS is predicated on small tumor size, so further increases in its use are explained principally by a decrease in tumor diameter. The increase in the rate of BCS for stage II disease also may be partially due to increased utilization of neoadjuvant therapy. However, a relationship cannot be determined using data from the RICR. Physician bias and known higher local recurrence in younger patients may account to some extent for the observation that there was no increase in BCS utilization in women 40-49 years of age. 49, 50 Earlier stage, smaller tumor size, and decreased rates of nodal metastases should lead to a decreased mortality. 16, 17, 21, 58 Early detection and continued advances in the treatment of breast cancer have resulted in a 25% decrease in disease-specific mortality in Rhode Island over the past 15 years, from 35.4 to 28.1 per 100,000 (Fig 6) . The US breast cancer mortality over the same time decreased only 13%, from 33.0 to 28.8 per 100,000. 34 The Healthy People 2010 goal for breast cancer mortality is 22.2 per 100,000, 29 indicating that continued screening efforts to detect smaller tumors must be encouraged. A recent study in Rhode Island showed that 73% of deaths attributed to breast cancer occurred in women who had received no mammographic screening in the prior 2 years. This population of underscreened women should be targeted in order to further reduce disease-related mortality. 59 When the mortality is examined by age groups, the only statistically significant decrease in breast cancer mortality is within women age 50-64 years, although there is a strong trend for decreased mortality for those 40-49 years of age. Since the data are derived from death certificates, there is often difficulty in determining the primary cause of death and the number of cases with active disease who die of other competing causes. Despite this significant decrease in disease-specific mortality, there has been no decrease in the overall mortality for any age group. As the breast cancer mortality continues to decrease due to early detection and improved treatment options, perhaps there will be a decrease in overall mortality within some groups.
Conclusions
Increased public awareness and physician education in Rhode Island have led to high rates of mammography in all age groups. This has been associated with smaller tumor size and fewer women presenting with advanced disease. The disease-specific mortality rate in the state has decreased significantly. Since tumors are now found at an smaller size and earlier stage, women have more choices in therapy and treatment options that are more effective and less morbid.
